Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Wednesday

Pasithea Therapeutics (NASDAQ:KTTA) is anticipated to release its results after the market closes on Wednesday, June 3rd. Analysts expect Pasithea Therapeutics to post earnings of ($3.40) per share and revenue of $0.30 million for the quarter.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.33. On average, analysts expect Pasithea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pasithea Therapeutics Trading Down 2.8%

Shares of Pasithea Therapeutics stock opened at $0.68 on Wednesday. The stock has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.85. Pasithea Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.06. The company has a market capitalization of $16.96 million, a P/E ratio of -0.33 and a beta of 0.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Squadron Capital Management LLC purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at $2,709,000. Janus Henderson Group PLC purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at $2,720,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at $2,709,000. Vivo Capital LLC purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at $2,709,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Pasithea Therapeutics during the 4th quarter valued at $375,000. Hedge funds and other institutional investors own 23.92% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on KTTA. Zacks Research downgraded Pasithea Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Pasithea Therapeutics in a report on Monday, April 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Friday, March 27th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $3.00.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.